X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA SANOFI INDIA NATCO PHARMA/
SANOFI INDIA
 
P/E (TTM) x 23.5 33.6 70.1% View Chart
P/BV x 17.8 6.4 278.7% View Chart
Dividend Yield % 0.6 1.4 45.5%  

Financials

 NATCO PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
SANOFI INDIA
Dec-16
NATCO PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs8774,560 19.2%   
Low Rs4244,400 9.6%   
Sales per share (Unadj.) Rs223.41,028.5 21.7%  
Earnings per share (Unadj.) Rs31.1129.0 24.1%  
Cash flow per share (Unadj.) Rs40.3186.0 21.7%  
Dividends per share (Unadj.) Rs5.0068.00 7.4%  
Dividend yield (eoy) %0.81.5 50.7%  
Book value per share (Unadj.) Rs219.5753.6 29.1%  
Shares outstanding (eoy) m33.0723.03 143.6%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.94.4 66.8%   
Avg P/E ratio x20.934.7 60.3%  
P/CF ratio (eoy) x16.124.1 67.0%  
Price / Book Value ratio x3.05.9 49.8%  
Dividend payout %16.152.7 30.5%   
Avg Mkt Cap Rs m21,504103,174 20.8%   
No. of employees `000NA3.6 0.0%   
Total wages/salary Rs m1,1283,592 31.4%   
Avg. sales/employee Rs ThNM6,537.7-  
Avg. wages/employee Rs ThNM991.4-  
Avg. net profit/employee Rs ThNM819.8-  
INCOME DATA
Net Sales Rs m7,38923,686 31.2%  
Other income Rs m167708 23.6%   
Total revenues Rs m7,55624,394 31.0%   
Gross profit Rs m1,7935,281 34.0%  
Depreciation Rs m3041,313 23.2%   
Interest Rs m36615 2,441.3%   
Profit before tax Rs m1,2904,661 27.7%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3091,691 18.3%   
Profit after tax Rs m1,0272,970 34.6%  
Gross profit margin %24.322.3 108.9%  
Effective tax rate %23.936.3 66.0%   
Net profit margin %13.912.5 110.9%  
BALANCE SHEET DATA
Current assets Rs m3,68115,673 23.5%   
Current liabilities Rs m3,1236,678 46.8%   
Net working cap to sales %7.638.0 19.9%  
Current ratio x1.22.3 50.2%  
Inventory Days Days8976 117.8%  
Debtors Days Days5922 263.0%  
Net fixed assets Rs m7,6858,098 94.9%   
Share capital Rs m331230 143.6%   
"Free" reserves Rs m6,67017,088 39.0%   
Net worth Rs m7,25917,356 41.8%   
Long term debt Rs m9550-   
Total assets Rs m11,95725,400 47.1%  
Interest coverage x4.5311.7 1.5%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.9 66.3%   
Return on assets %11.711.8 99.2%  
Return on equity %14.217.1 82.7%  
Return on capital %20.726.9 76.9%  
Exports to sales %39.424.5 160.7%   
Imports to sales %5.728.0 20.4%   
Exports (fob) Rs m2,9085,801 50.1%   
Imports (cif) Rs m4216,627 6.4%   
Fx inflow Rs m3,4457,145 48.2%   
Fx outflow Rs m7036,846 10.3%   
Net fx Rs m2,743299 917.3%   
CASH FLOW
From Operations Rs m1,4403,226 44.6%  
From Investments Rs m-1,089-1,555 70.0%  
From Financial Activity Rs m-353-1,818 19.4%  
Net Cashflow Rs m-1-147 1.0%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 60.4 2.4%  
Indian inst/Mut Fund % 7.8 14.4 54.4%  
FIIs % 16.6 14.6 113.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 10.5 247.6%  
Shareholders   25,395 15,184 167.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   SUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  CADILA HEALTHCARE  UNICHEM LAB  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS